Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check2 days agoChange DetectedAn NIH grant/contract attribution (2018) was added to the study's identifiers, and the page now shows Revision: v3.6.6, replacing the previous v3.6.5.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, reflecting a newer iteration of the page content; this is a metadata-level change rather than a substantive update to study details.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page now displays Revision: v3.6.4, replacing the previous v3.6.3, indicating a newer version of the study protocol/documentation referenced on the page.SummaryDifference0.0%

- Check59 days agoChange DetectedA new page revision label, v3.6.3, has been added (replacing v3.6.2), indicating a minor update to the page.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2 to reflect a newer version of the page.SummaryDifference0.0%

- Check81 days agoChange DetectedRecruitment status on the study page now shows 'No longer looking for participants,' indicating enrollment is complete. The page also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and standardizes the Intervention/Treatment label, with the revision tag updated to v3.6.0.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.